{"id":"eligard","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Hot flashes/sweats","drugRate":"73.3%","severity":"common","organSystem":""},{"effect":"Transient burning/stinging at injection site","drugRate":"34.6%","severity":"mild","organSystem":""},{"effect":"Pain at injection site","drugRate":"18.3%","severity":"mild","organSystem":""}],"contraindications":["Breastfeeding (mother)","Cardiovascular event risk","Cerebrovascular accident","Diabetes mellitus","Hypercholesterolemia","Hyperglycemia","Hypertensive disorder","Myocardial infarction","Obesity","Orchiectomy","Osteopenia","Pregnancy, function","Smokes tobacco daily","Urinary tract obstruction","Vertebral Metastases"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Neurological problems (weakness and/or paresthesia of lower limbs)","drugRate":"","severity":"serious"},{"effect":"Worsening of urinary symptoms","drugRate":"","severity":"serious"},{"effect":"Exacerbation of vertebral metastases symptoms","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["Leuprorelin acetate","Radiation","Leuproréline"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"b7b679a9-6823-4ef8-8d31-3ab5058ffcfc","title":"ELIGARD (LEUPROLIDE ACETATE) INJECTION, SUSPENSION, EXTENDED RELEASE [TOLMAR INC.]"},"ecosystem":[],"mechanism":{"target":"Gonadotropin-releasing hormone receptor, Gonadotropin-releasing hormone receptor"},"_scrapedAt":"2026-03-27T23:29:07.653Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"url":"https://en.wikipedia.org/wiki/Leuprorelin","title":"Leuprorelin","extract":"Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, for early puberty, as part of transgender hormone therapy, or to perform chemical castration of violent sex offenders. It is given by injection into a muscle or under the skin."},"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Advanced Prostatic Carcinoma","diseaseId":"advanced-prostatic-carcinoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Anemia due to Bleeding Uterine Leiomyoma","diseaseId":"anemia-due-to-bleeding-uterine-leiomyoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Endometriosis","diseaseId":"endometriosis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Precocious puberty","diseaseId":"precocious-puberty","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05593497","phase":"PHASE2","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-31","conditions":"High-Risk Prostate Cancer","enrollment":30},{"nctId":"NCT06832774","phase":"PHASE2","title":"Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-01","conditions":"Prostate Cancer Metastatic Disease","enrollment":192},{"nctId":"NCT05567198","phase":"","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2023-03-03","conditions":"Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)","enrollment":100},{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT06169124","phase":"PHASE2","title":"Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-08","conditions":"Adult Ovarian Granulosa Cell Tumor","enrollment":37},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT07027124","phase":"PHASE2","title":"Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03-19","conditions":"Prostate Cancer, High-risk Prostate Cancer","enrollment":40},{"nctId":"NCT03573648","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-13","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT07477626","phase":"PHASE3","title":"Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-06","conditions":"Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic","enrollment":374},{"nctId":"NCT06654336","phase":"PHASE2","title":"Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)","status":"RECRUITING","sponsor":"Ontario Clinical Oncology Group (OCOG)","startDate":"2026-03-30","conditions":"Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer","enrollment":162},{"nctId":"NCT04557059","phase":"PHASE3","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-11-12","conditions":"Prostatic Neoplasms","enrollment":693},{"nctId":"NCT04293393","phase":"PHASE2","title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2020-10-02","conditions":"Early Breast Cancer","enrollment":200},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT04931342","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-10-07","conditions":"Ovarian Cancer","enrollment":176},{"nctId":"NCT07182279","phase":"PHASE1, PHASE2","title":"Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-08-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":29},{"nctId":"NCT06330805","phase":"PHASE2","title":"Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-08-12","conditions":"Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT00936390","phase":"PHASE3","title":"Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2009-09","conditions":"Prostate Cancer","enrollment":1538},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":239},{"nctId":"NCT07455903","phase":"PHASE2","title":"Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT","status":"NOT_YET_RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2026-04","conditions":"Prostate Cancer, Localized Prostate Carcinoma","enrollment":50},{"nctId":"NCT07444983","phase":"NA","title":"Rezvilutamide for High-Risk Prostate Cancer After Surgery","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2026-02-11","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":33},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT07015268","phase":"PHASE3","title":"A Clinical Study of KLH-2109 in Patients With Endometriosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kissei Pharmaceutical Co., Ltd.","startDate":"2025-06-09","conditions":"Endometriosis","enrollment":288},{"nctId":"NCT05827081","phase":"PHASE3","title":"Phase IIIb Study of Ribociclib + ET in Early Breast Cancer","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-28","conditions":"Early Breast Cancer","enrollment":1400},{"nctId":"NCT04423211","phase":"PHASE3","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-10-08","conditions":"Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":804},{"nctId":"NCT05700903","phase":"PHASE4","title":"Contributions to Hypertension With Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-09-20","conditions":"Androgen Deprivation Therapy, Prostate Cancer, Hypertension","enrollment":10},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT06650579","phase":"PHASE3","title":"REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-31","conditions":"Recurrent Prostate Carcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":72},{"nctId":"NCT01786265","phase":"PHASE2","title":"Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-05","conditions":"Prostate Adenocarcinoma, Recurrent Prostate Carcinoma","enrollment":310},{"nctId":"NCT06305598","phase":"PHASE1","title":"Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2024-12-19","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":14},{"nctId":"NCT07158021","phase":"PHASE2","title":"Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2026-01-22","conditions":"Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8","enrollment":75},{"nctId":"NCT02274779","phase":"PHASE2","title":"Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer","status":"COMPLETED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2014-08-20","conditions":"Prostate Cancer","enrollment":74},{"nctId":"NCT03332797","phase":"PHASE1","title":"A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2017-11-24","conditions":"Breast Cancer","enrollment":181},{"nctId":"NCT05320406","phase":"PHASE2","title":"RElugolix VErsus LeUprolide Cardiac Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2022-06-06","conditions":"Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8","enrollment":94},{"nctId":"NCT06627530","phase":"PHASE4","title":"COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2025-02-17","conditions":"Prostate Cancer","enrollment":144},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT07389174","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mHSPC, mHNPC, Prostate Cancer Adenocarcinoma","enrollment":40},{"nctId":"NCT03902951","phase":"PHASE2","title":"Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2021-03-17","conditions":"Metastatic Prostate Adenocarcinoma, Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation, Recurrent Prostate Carcinoma","enrollment":28},{"nctId":"NCT07389187","phase":"EARLY_PHASE1","title":"Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mCRPC","enrollment":10},{"nctId":"NCT04455750","phase":"PHASE3","title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2021-10-14","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":61},{"nctId":"NCT06394804","phase":"PHASE2","title":"A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-04-29","conditions":"Low-Grade Serous Ovarian Cancer","enrollment":20},{"nctId":"NCT05701007","phase":"","title":"Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-13","conditions":"Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":1083},{"nctId":"NCT06397703","phase":"PHASE2","title":"ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-04-16","conditions":"Prostate Cancer","enrollment":392},{"nctId":"NCT04734730","phase":"PHASE2","title":"Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-05-04","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":70},{"nctId":"NCT02772588","phase":"PHASE2","title":"AASUR in High Risk Prostate Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-05-12","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT05498272","phase":"PHASE2","title":"Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations","status":"RECRUITING","sponsor":"Rana McKay, MD","startDate":"2023-02-01","conditions":"Prostate Cancer, BRCA1 Mutation, BRCA2 Mutation","enrollment":32},{"nctId":"NCT04126070","phase":"PHASE2","title":"Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiao X. Wei, MD","startDate":"2020-05-11","conditions":"Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma","enrollment":60},{"nctId":"NCT06734130","phase":"PHASE2","title":"Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-01-10","conditions":"Metastatic Castration Sensitive Prostate Cancer","enrollment":25},{"nctId":"NCT03070886","phase":"PHASE2, PHASE3","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2017-04-05","conditions":"Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7","enrollment":612},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT07340619","phase":"PHASE2","title":"Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-18","conditions":"Metastatic (Stage IV) Melanoma","enrollment":51},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":"Prostate Adenocarcinoma","enrollment":2050},{"nctId":"NCT04513717","phase":"PHASE3","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"NRG Oncology","startDate":"2021-01-21","conditions":"Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8","enrollment":2753},{"nctId":"NCT05341115","phase":"PHASE4","title":"A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-03-14","conditions":"Central Precocious Puberty","enrollment":80},{"nctId":"NCT03056755","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-08-29","conditions":"Breast Cancer","enrollment":383},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT02454543","phase":"NA","title":"Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Martini-Klinik am UKE GmbH","startDate":"2015-05","conditions":"Prostate Cancer","enrollment":452},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT01746849","phase":"PHASE2","title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Leukemia, Multiple Myeloma, Myelodysplastic Syndrome","enrollment":82},{"nctId":"NCT05122377","phase":"","title":"RWE About QOL and Compliance of Patients With OFS in China","status":"COMPLETED","sponsor":"Fudan University","startDate":"2022-03-01","conditions":"Breast Cancer, Quality of Life, Hormone Receptor-positive Breast Cancer","enrollment":562},{"nctId":"NCT01809691","phase":"PHASE3","title":"S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2013-03-08","conditions":"Prostate Cancer","enrollment":1313},{"nctId":"NCT07313241","phase":"PHASE2","title":"Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-11-14","conditions":"Prostate Cancer","enrollment":68},{"nctId":"NCT03809000","phase":"PHASE2","title":"A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2019-04-15","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT00329043","phase":"PHASE2","title":"Sunitinib Malate With Hormonal Ablation for Patients Who Will Have Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-05-15","conditions":"Prostate Cancer","enrollment":64},{"nctId":"NCT06849947","phase":"PHASE2","title":"Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Yeon Hee Park","startDate":"2026-02-01","conditions":"Breast Cancer Metastatic","enrollment":272},{"nctId":"NCT05873192","phase":"PHASE2","title":"Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-06-03","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT05241860","phase":"PHASE2","title":"Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2022-11-21","conditions":"Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":79},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":"Prostate Cancer","enrollment":504},{"nctId":"NCT02960022","phase":"PHASE2","title":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-12-22","conditions":"Prostate Cancer","enrollment":900},{"nctId":"NCT04034095","phase":"","title":"A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2019-07-08","conditions":"Prostatic Neoplasms","enrollment":979},{"nctId":"NCT07268794","phase":"PHASE2","title":"CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-11-30","conditions":"Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":112},{"nctId":"NCT00001481","phase":"PHASE2","title":"The Role of Hormones in Postpartum Mood Disorders","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1996-04-26","conditions":"Postpartum Depression","enrollment":74},{"nctId":"NCT03007732","phase":"PHASE2","title":"Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT","status":"COMPLETED","sponsor":"David Oh","startDate":"2017-05-17","conditions":"Prostatic Neoplasms","enrollment":23},{"nctId":"NCT03511196","phase":"EARLY_PHASE1","title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-17","conditions":"Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer","enrollment":17},{"nctId":"NCT05189457","phase":"PHASE2","title":"First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-01-25","conditions":"Prostate Cancer, Stage IV Prostate Cancer","enrollment":32},{"nctId":"NCT07159451","phase":"PHASE2","title":"A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2025-10-06","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT05924256","phase":"PHASE2","title":"A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2023-07-26","conditions":"Advanced Salivary Gland Carcinoma","enrollment":88},{"nctId":"NCT02023463","phase":"PHASE1","title":"Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2014-04-02","conditions":"Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIB Prostate Cancer","enrollment":25},{"nctId":"NCT03519178","phase":"PHASE1, PHASE2","title":"A Study of PF-06873600 in People With Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-03-07","conditions":"HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer","enrollment":155},{"nctId":"NCT04569747","phase":"PHASE2","title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-01-11","conditions":"HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer","enrollment":375},{"nctId":"NCT05669664","phase":"PHASE2","title":"Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-07-20","conditions":"Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma","enrollment":21},{"nctId":"NCT05628363","phase":"NA","title":"Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-18","conditions":"Prostate Cancer, Cancer of the Prostate","enrollment":28},{"nctId":"NCT05100472","phase":"PHASE2","title":"A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-10-19","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT03555578","phase":"","title":"Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg \"All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)\"","status":"RECRUITING","sponsor":"Takeda","startDate":"2017-11-02","conditions":"Spinal and Bulbar Muscular Atrophy","enrollment":1890},{"nctId":"NCT05896293","phase":"PHASE2","title":"Kisspeptin Administration Subcutaneously to Patients With IHH","status":"RECRUITING","sponsor":"Stephanie B. Seminara, MD","startDate":"2023-02-03","conditions":"Hypogonadotropic Hypogonadism","enrollment":36},{"nctId":"NCT06449027","phase":"PHASE3","title":"Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2024-08-21","conditions":"Breast Cancer Subjects","enrollment":211},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT07187947","phase":"","title":"Cardiovascular Health of Transgender Individuals During the Gender-affirming Pathway","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2025-07-18","conditions":"Gender Incongruence, Cardiovascular (CV) Risk, Cardiovascular Disease Risk Factor","enrollment":500},{"nctId":"NCT06348264","phase":"PHASE2","title":"Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-10-10","conditions":"Salivary Gland Neoplasm Duct","enrollment":37},{"nctId":"NCT05493709","phase":"PHASE3","title":"Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foresee Pharmaceuticals Co., Ltd.","startDate":"2023-06-02","conditions":"Puberty; Precocious, Central","enrollment":93},{"nctId":"NCT02972060","phase":"PHASE2","title":"ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2017-12-01","conditions":"Prostate Cancer","enrollment":61},{"nctId":"NCT07179939","phase":"PHASE2","title":"Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-10","conditions":"HER2-positive Breast Cancer","enrollment":288},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT03678025","phase":"PHASE3","title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2018-09-24","conditions":"Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":1273},{"nctId":"NCT06512207","phase":"NA","title":"A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer","status":"RECRUITING","sponsor":"Jinzhou Medical University","startDate":"2023-12-03","conditions":"NSCLC, Stage III, NSCLC, Stage IV","enrollment":80},{"nctId":"NCT05063786","phase":"PHASE3","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2021-09-14","conditions":"Advanced Breast Cancer","enrollment":27},{"nctId":"NCT01492972","phase":"PHASE3","title":"Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"Proton Collaborative Group","startDate":"2012-01","conditions":"Prostate Cancer","enrollment":192},{"nctId":"NCT07142967","phase":"NA","title":"Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-08-15","conditions":"Intraprostatic Prostate Cancer","enrollment":28}],"_emaApprovals":[],"_faersSignals":[{"count":8679,"reaction":"INTERCEPTED PRODUCT PREPARATION ERROR"},{"count":7711,"reaction":"SYRINGE ISSUE"},{"count":6015,"reaction":"HOT FLUSH"},{"count":5874,"reaction":"DEVICE LEAKAGE"},{"count":5824,"reaction":"DEATH"},{"count":5095,"reaction":"WRONG TECHNIQUE IN PRODUCT USAGE PROCESS"},{"count":4128,"reaction":"INJECTION SITE PAIN"},{"count":3130,"reaction":"FATIGUE"},{"count":1749,"reaction":"PROSTATIC SPECIFIC ANTIGEN INCREASED"},{"count":1629,"reaction":"INTENTIONAL PRODUCT USE ISSUE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[{"date":"20130409","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20020401","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20101005","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20151026","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20141010","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20020123","type":"ORIG","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20110408","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20250204","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20230720","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20190215","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20240123","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20140530","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20040112","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20130227","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20110114","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20030703","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20160229","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20141010","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20071108","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20250224","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20230720","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20240521","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20140718","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20170113","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021343"},{"date":"20160229","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20221125","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20141010","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20071108","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20130227","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20110408","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20250224","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20240521","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20230720","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20060929","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20140718","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20130403","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20110114","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20101005","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20041214","type":"ORIG","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20250204","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20230720","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20190215","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20240123","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021731"},{"date":"20140203","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20190215","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20040112","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20160229","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20130227","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20130208","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20110114","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20250204","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20230720","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20140415","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20140718","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20110408","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20141010","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20130125","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20101005","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20020724","type":"ORIG","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20250224","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20071108","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20230720","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20240521","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20240123","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021379"},{"date":"20101005","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20240123","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20250204","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20230720","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20190215","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20240521","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20040112","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20110114","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20160229","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20071108","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20030213","type":"ORIG","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20250224","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20230720","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20141010","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20130227","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"},{"date":"20110408","type":"SUPPL","sponsor":"TOLMAR","applicationNumber":"NDA021488"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":30,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Eligard","genericName":"Eligard","companyName":"Astellas Pharma Europe Ltd.","companyId":"astellas-pharma-europe-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":243,"withResults":45},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}